Shares of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $147.75.
MDGL has been the subject of a number of recent research reports. HC Wainwright increased their target price on Madrigal Pharmaceuticals from $105.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research cut Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Roth Capital set a $82.00 price target on Madrigal Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 30th. JMP Securities raised their price target on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a report on Friday, October 13th. Finally, BidaskClub raised Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th.
Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) opened at $145.99 on Thursday. Madrigal Pharmaceuticals has a 52 week low of $13.09 and a 52 week high of $154.75. The firm has a market capitalization of $2,003.23, a P/E ratio of -57.48 and a beta of 1.19.
A number of hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. increased its holdings in Madrigal Pharmaceuticals by 303.9% during the 4th quarter. Victory Capital Management Inc. now owns 204,206 shares of the biopharmaceutical company’s stock valued at $18,744,000 after purchasing an additional 153,650 shares in the last quarter. Jennison Associates LLC acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $18,744,000. Northern Trust Corp increased its holdings in Madrigal Pharmaceuticals by 151.2% during the 2nd quarter. Northern Trust Corp now owns 50,069 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 30,134 shares in the last quarter. State Street Corp acquired a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $539,000. Finally, VHCP Management II LLC acquired a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $1,349,000. 20.53% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Madrigal Pharmaceuticals Inc (MDGL) Receives Average Recommendation of “Buy” from Analysts” was originally posted by registrarjournal.com and is the sole property of of registrarjournal.com. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://registrarjournal.com/2018/02/08/madrigal-pharmaceuticals-inc-mdgl-receives-average-recommendation-of-buy-from-analysts.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.